BRÈVE

sur SynBiotic SE (isin : DE000A3E5A59)

SYNBIOTIC Enhances Global Presence and Advances Cannabis Research

The European medical cannabis group, SYNBIOTIC SE, is expanding its strategic initiatives by strengthening its global presence through participation in key international events. Having engaged with the Talman House Roadshow in London, SYNBIOTIC is set to join the Equity Capital Forum in Frankfurt, aiming to highlight advancements in healthcare, food, beverage, and consumer goods sectors.

In London, SYNBIOTIC took the opportunity to network with investors and partners, emphasizing the growing importance of full-spectrum CBD products. Recent research underlines the benefits of the entourage effect — the combined interaction of cannabinoids and terpenes. SYNBIOTIC is capitalizing on this by developing full-spectrum cannabis extracts with far-reaching medical applications.

SYNBIOTIC is demonstrating commitment to advancing regulatory frameworks, advocating for the recognition of CBD products beyond isolated substances. This initiative underscores SYNBIOTIC’s focus on expanding its business while reducing risks for investors.

R. E.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SynBiotic SE